← All diseases
Lungs and airways
Pulmonary fibrosis (IPF)
Would you like to receive a message when there is new research on Idiopathic Pulmonary Fibrosis (IPF)? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, above each publication you'll find one sentence explaining what was researched — and you'll receive a notification as soon as there is new research on Pulmonary Fibrosis (IPF). View what Premium costs.
Publications and studies (1942)
- Protection of Qingfei Xieding prescription from idiopathic pulmonary fibrosis by regulating renin-angiotensin and ferroptosis in MLE-12 cells. (2024/12/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Xuanfei Baidu decoction ameliorates bleomycin-elicited idiopathic pulmonary fibrosis in mice by regulating the lung-gut crosstalk via IFNγ/STAT1/STAT3 axis. (2024/12/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Body mass index and weight loss as risk factors for poor outcomes in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. (2024/12/01) ♡
- Enhanced oxidative stress aggravates BLM-induced pulmonary fibrosis by promoting cellular senescence through enhancing NLRP3 activation. (2024/12/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Contemporary Concise Review 2023: Interstitial lung disease. (2024/12/01) ♡
- Patient-Reported Outcome Scale for Idiopathic Pulmonary Fibrosis: Development and Validation in China. (2024/12/01) ♡
- An important radiological clue in idiopathic pulmonary fibrosis: Diffuse pulmonary ossification. (2024/12/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. [Evidence mapping of clinical research on traditional Chinese medicine in treatment of idiopathic pulmonary fibrosis]. (2024/12/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [Effect of Fuzheng Tongluo Granules on macrophage pyroptosis in rat model with pulmonary fibrosis based on NLRP3/caspase-1/GSDMD pathway]. (2024/12/01) ♡
- Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline. (2024/12/01) ♡
- Development of a local nomogram-based scoring system for predicting overall survival in idiopathic pulmonary fibrosis: A rural appalachian experience. (2024/12/01) ♡
- The naturally occurring peptide GHK reverses age-related fibrosis by modulating myofibroblast function. (2024/12/01) ♡
- Establishment and validation of a prognostic model for idiopathic pulmonary fibrosis based on mitochondrial-related genes. (2024/11/30) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Genetic Risk Factors in Idiopathic and Non-Idiopathic Interstitial Lung Disease: Similarities and Differences. (2024/11/29) ♡
- Mitochondrial Transplantation Ameliorates Pulmonary Fibrosis by Suppressing Myofibroblast Activation. (2024/11/28) ♡
- Investigating the Potential of Ufasomes Laden with Nintedanib as an Optimized Targeted Lung Nanoparadigm for Accentuated Tackling of Idiopathic Pulmonary Fibrosis. (2024/11/28) ♡
- The Application of Mesenchymal Stem Cell Therapy in Treating Pulmonary Fibrosis: A Scoping Review. (2024/11/27) ♡
- Differences Between Patients with Probable UIP and Definite UIP on HRCT in Idiopathic Pulmonary Fibrosis: A Real-World Cohort Study. (2024/11/26) ♡
- B-Lightning: using bait genes for marker gene hunting in single-cell data with complex heterogeneity. (2024/11/22) ♡
- A dual αvβ1/αvβ6 integrin inhibitor Bexotegrast (PLN-74809) ameliorates organ injury and fibrogenesis in fibrotic kidney disease. (2024/11/15) ♡
- Spirotetrahydroisoquinoline-Based Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis Patients. (2024/11/12) ♡
- Cell Membrane Hybrid Liposome-Targeted Delivery of the Heat Shock Protein 90 C-Terminal Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis. (2024/11/05) ♡
- Insights on the Tunisian Prickly Pear Molasses as a Potential Antifibrotic and Antioxidant Candidate against Lung Fibrosis. (2024/11/01) ♡
- Prevalence and prognostic value of malnutrition in patients with IPF using three scoring systems. (2024/11/01) ♡
- Cannabinoid receptor ligands modulate fibrosis and inflammation in idiopathic pulmonary fibrosis: a preliminary study. (2024/10/23) ♡
- Corrigendum: Identification of oxidative stress-related diagnostic markers and immune infiltration features for idiopathic pulmonary fibrosis by bibliometrics and bioinformatics. (2024/10/16) ♡
- The Prognostic Role of Advanced Lung Cancer Inflammation Index in Patients with Idiopathic Pulmonary Fibrosis. (2024/10/02) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Outcomes of lung transplantation for pleuroparenchymal fibroelastosis: A French multicentric retrospective study. (2024/10/01) ♡
- Interactions between fibroblasts and monocyte-derived cells in chronic lung injuries induced by real-ambient particulate matter exposure. (2024/10/01) ♡
- A pilot metabolomics study across the continuum of interstitial lung disease fibrosis severity. (2024/10/01) ♡
- [Organizing Pneumonia: Analysis of 10 Years Registers in a Chilean Center]. (2024/10/01) ♡
- LPA(1) antagonist-derived LNPs deliver A20 mRNA and promote anti-fibrotic activities. (2024/10/01) ♡
- Are the gains from pulmonary rehabilitation the same in idiopathic pulmonary fibrosis and other interstitial lung diseases? (2024/09/24) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Pirfenidone-induced liver injury, a case report of a rare idiosyncratic reaction. (2024/09/14) ♡
- A Continuous Intestinal Absorption Model to Predict Drug Enterohepatic Recirculation in Healthy Humans: Nalbuphine as a Model Substrate. (2024/09/02) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. ESL attenuates BLM-induced IPF in mice: Dual mediation of the TLR4/NF-κB and TGF-β1/PI3K/Akt/FOXO3a pathways. (2024/09/01) ♡
- Pirfenidone ameliorates ANIT-induced cholestatic liver injury via modulation of FXR, NF-кB/TNF-α, and Wnt/GSK-3β/β-catenin signaling pathways. (2024/09/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Idiopathic pulmonary fibrosis (IPF): disease pathophysiology, targets, and potential therapeutic interventions. (2024/09/01) ♡
- Fasting alleviates bleomycin-induced lung inflammation and fibrosis via decreased Tregs and monocytes. (2024/09/01) ♡
- Usefulness of serum transthyretin for prediction of the 1-year outcome in idiopathic pulmonary fibrosis: An evaluation of sarcopenic and nutritional indicators. (2024/09/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. IA-Body Composition CT at T12 in Idiopathic Pulmonary Fibrosis: Diagnosing Sarcopenia and Correlating with Other Morphofunctional Assessment Techniques. (2024/08/28) ♡
- Preparation, Characterization and Evaluation of Nintedanib Amorphous Solid Dispersions with Enhanced Oral Bioavailability. (2024/08/13) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Identification of oxidative stress-related diagnostic markers and immune infiltration features for idiopathic pulmonary fibrosis by bibliometrics and bioinformatics. (2024/08/06) ♡
- The mechanism of action of Botrychium (Thunb.) Sw. for prevention of idiopathic pulmonary fibrosis based on 1H-NMR-based metabolomics. (2024/08/02) ♡
- Screening study on significant Chinese herb for anti-idiopathic pulmonary fibrosis by combining clinical experience prescriptions and molecular dynamics simulation technologies. (2024/08/01) ♡
- Modafinil exerts anti-inflammatory and anti-fibrotic effects by upregulating adenosine A(2A) and A(2B) receptors. (2024/08/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Respiratory Diseases Associated With Organic Dust Exposure. (2024/08/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Shengxian decoction improves lung function in rats with bleomycin-induced idiopathic pulmonary fibrosis through the inhibition of PANoptosis. (2024/07/15) ♡
- Association between swallowing dynamics, tongue pressure and pulmonary function in patients with idiopathic pulmonary fibrosis. (2024/07/04) ♡
- Deep learning-based prognostication in idiopathic pulmonary fibrosis using chest radiographs. (2024/07/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.